Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis

被引:58
作者
Amoako, Afia [1 ]
Ortiz-Paredes, David [2 ]
Engler, Kim [2 ]
Lebouche, Bertrand [2 ,3 ,4 ,6 ]
Klein, Marina B. [4 ,5 ]
机构
[1] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, 1020 Pine Ave West, Montreal, PQ H3A 1A2, Canada
[2] McGill Univ, Hlth Ctr, Res Inst, Ctr Outcomes Res & Evaluat, 5252 Boul Maisonneuve, Montreal, PQ H4A 3S5, Canada
[3] McGill Univ, Dept Family Med, 5858 Cote des Neiges Rd, Montreal, PQ H3S 1Z1, Canada
[4] McGill Univ, Hlth Ctr, Dept Med, Div Infect Dis,Chron Viral Illness Serv, 1001 Decarie Blvd D02-4110, Montreal, PQ H4A 3J1, Canada
[5] CIHR Canadian HIV Trials Network, 588-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada
[6] Canadian Inst Hlth Res Strategy Patient Oriented, Innovat Clin Trials HIV, Montreal, PQ, Canada
关键词
Hepatitis C; Direct-acting antivirals; Qualitative; Indigenous; People who inject drugs; Systematic review; HCV TREATMENT; DRUG-USERS; PEOPLE; SYSTEM; CARE; CURE;
D O I
10.1016/j.drugpo.2021.103247
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Direct acting antivirals (DAAs) have increased cure rates for hepatitis C virus (HCV) infection; however, there are several obstacles to the uptake of DAAs in populations where substance use contributes to HCV risk. This synthesis aimed to identify the patient and provider perceived barriers and facilitators to DAA treatment initiation in key patient subgroups-people who inject drugs (PWID), men who have sex with men (MSM), and Indigenous people. Methods: We systematically searched seven databases and conducted a gray literature search for studies that qualitatively explored patient and provider perceived barriers and facilitators to DAA treatment in our populations of interest. Selected studies were published after 2013 when second generation DAAs became available. The titles, abstracts, and subsequently full texts were screened by two independent reviewers and critically appraised. Barriers and facilitators to DAA treatment uptake were then extracted and thematically synthesized. Results: 2144 titles and abstracts were identified and screened; 29 full texts were subsequently reviewed. Twelve qualitative studies were finally included. Among providers, perceived barriers to DAA treatment uptake included lack of resources and lack of provider knowledge on HCV while facilitators to treatment provision included simplicity of DAA regimens and professional identity as a doctor to advocate for patients. Among patients, perceived barriers to treatment uptake included current drug use, concerns about side effects of DAAs, stigma, gaps in community care, competing social responsibilities and mental health issues while facilitators included having a trustworthy provider and access to multidisciplinary HCV care. Conclusion: Despite simplicity of DAAs, many structural barriers to optimal HCV care continue to be experienced by patients and providers. In highlighting nuanced patient and provider perceived barriers and facilitators, this review underscores the need to involve participatory methods in the design and evaluation of interventions to best improve access to care.
引用
收藏
页数:11
相关论文
共 35 条
[1]  
[Anonymous], 2019, Hepatitis C
[2]  
Bartholomew Tyler S, 2019, Infect Dis (Auckl), V12, p1178633719841381, DOI 10.1177/1178633719841381
[3]   Making sense of 'side effects': Counterpublic health in the era of direct-acting antivirals [J].
Bryant, Joanne ;
Rance, Jake ;
Hull, Peter ;
Mao, Limin ;
Treloar, Carla .
INTERNATIONAL JOURNAL OF DRUG POLICY, 2019, 72 :77-83
[4]   Reducing patient and provider knowledge gaps: An evaluation of a community informed hepatitis C online course [J].
Buller-Taylor, Terri ;
McGuinness, Liza ;
Yan, Melissa ;
Janjua, Naveed Z. .
PATIENT EDUCATION AND COUNSELING, 2018, 101 (06) :1095-1102
[5]   Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs [J].
Childs, Ellen ;
Assoumou, Sabrina A. ;
Biello, Katie B. ;
Biancarelli, Dea L. ;
Drainoni, Mari-Lynn ;
Edeza, Alberto ;
Salhaney, Peter ;
Mimiaga, Matthew J. ;
Bazzi, Angela R. .
HARM REDUCTION JOURNAL, 2019, 16 (1)
[6]   Pathways to ensure universal and affordable access to hepatitis C treatment [J].
Douglass, Caitlin H. ;
Pedrana, Alisa ;
Lazarus, Jeffrey V. ;
't Hoen, Ellen F. M. ;
Hammad, Radi ;
Leite, Ricardo Baptista ;
Hill, Andrew ;
Hellard, Margaret .
BMC MEDICINE, 2018, 16
[7]   "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs [J].
Goodyear, Trevor ;
Ti, Lianping ;
Carrieri, Patrizia ;
Small, Will ;
Knight, Rod .
INTERNATIONAL JOURNAL OF DRUG POLICY, 2020, 81
[8]   Breaking Down the Barriers to Hepatitis C Virus (HCV) Treatment Among Individuals With HCV/HIV Coinfection: Action Required at the System, Provider, and Patient Levels [J].
Grebely, Jason ;
Oser, Megan ;
Taylor, Lynn E. ;
Dore, Gregory J. .
JOURNAL OF INFECTIOUS DISEASES, 2013, 207 :S19-S25
[9]   Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors [J].
Harris, Magdalena ;
Rhodes, Tim .
HARM REDUCTION JOURNAL, 2013, 10
[10]   CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment [J].
Hull, Mark ;
Shafran, Stephen ;
Wong, Alex ;
Tseng, Alice ;
Giguere, Pierre ;
Barrett, Lisa ;
Haider, Shariq ;
Conway, Brian ;
Klein, Marina ;
Cooper, Curtis .
CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2016, 2016